Macro Finance
Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Case
Bloomberg Markets·September 24, 2026·1 min read
Kobayashi Pharmaceutical Co., the Japanese health products firm involved in a supplement contamination scandal with suspected deaths, is reportedly considering a buyout offer exceeding ¥500 billion ($3.2 billion) from private equity investors. The potential deal comes amid ongoing fallout from the red-yeast case.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.